Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023

Rhea-AI Summary

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) announced that it will release its fourth quarter and full year 2022 financial results on February 7, 2023. A live conference call and webcast will take place at 8:00 AM ET on the same day to discuss the results and provide a corporate update. The call will be accessible via a link on their website, with a replay available for 30 days after the event. Deciphera focuses on developing innovative cancer medicines, leveraging its kinase inhibitor platform, and has multiple clinical studies in progress, including the approved drug QINLOCK® for fourth-line GIST treatment.

Positive

• Upcoming earnings release may reveal positive financial metrics.
• Multiple product candidates in clinical studies could indicate growth potential.

Negative

• None.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023.

In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 8:00 AM ET on Tuesday, February 7, 2023, to discuss the Company’s financial results and provide a corporate update.

The conference call may be accessed via this link: https://register.vevent.com/register/BId831b7236a304519833842d99a13487f.

A live webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay will be available on the Company’s website approximately two hours after the conference call and will be available for 30 days following the call.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Israel, New Zealand, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20230131005351/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902



Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

When will Deciphera Pharmaceuticals report its fourth quarter 2022 financial results?

Deciphera Pharmaceuticals will report its fourth quarter 2022 financial results on February 7, 2023.

What time is Deciphera Pharmaceuticals' earnings conference call?

The earnings conference call for Deciphera Pharmaceuticals is scheduled for 8:00 AM ET on February 7, 2023.

How can I access the earnings call for Deciphera Pharmaceuticals?

You can access the earnings call for Deciphera Pharmaceuticals through a link provided on their website or directly via their events page.

What is QINLOCK® and its significance for Deciphera Pharmaceuticals?

QINLOCK® is Deciphera's approved drug for the treatment of fourth-line GIST, indicating the company's capability in developing impactful cancer therapies.